Literature DB >> 18067638

Immunohistochemical expression of TTF-1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity.

Akiko M Maeshima1, Mutsuko Omatsu, Koji Tsuta, Hisao Asamura, Yoshihiro Matsuno.   

Abstract

The immunohistochemical expression of thyroid transcription factor-1 (TTF-1) was investigated in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity. Three groups were categorized according to cytological subtype: group A, adenocarcinomas with either a Clara cell and/or type II epithelial cell component (Clara/type II) or a mixed Clara/type II and bronchial surface epithelial cell component (BSE) (mCB), in addition to other components; group B, adenocarcinomas with components including either BSE, a goblet cell component (GOB) or a mixed BSE and GOB component (mBG), and lacking Clara/type II or mCB; group C, adenocarcinomas with only a poorly differentiated component (POR). In group A all Clara/type II, mCB, BSE and the majority of POR were TTF-1 positive. In group B the majority of BSE, POR and all GOB were TTF-1 negative. BSE and POR in both groups had a different phenotype, possibly reflecting their different natural history. In group C 80% of cases were TTF-1 positive, suggesting that the majority were derived from group A tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18067638     DOI: 10.1111/j.1440-1827.2007.02185.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.

Authors:  Juliana G Carneiro; Patricia G Couto; Luciana Bastos-Rodrigues; Maria Aparecida C Bicalho; Paula V Vidigal; Alyne Vilhena; Nilson F Amaral; Allen E Bale; Eitan Friedman; Luiz De Marco
Journal:  Genet Res (Camb)       Date:  2014-03-05       Impact factor: 1.588

2.  KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.

Authors:  Yusuke Takanashi; Shogo Tajima; Takamitsu Hayakawa; Hiroshi Neyatani; Kazuhito Funai
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer.

Authors:  Ryo Nagashio; Junpei Ueda; Shinichiro Ryuge; Hiroyasu Nakashima; Shi-Xu Jiang; Makoto Kobayashi; Kengo Yanagita; Ken Katono; Yukitoshi Satoh; Noriyuki Masuda; Yoshiki Murakumo; Kazuo Hachimura; Yuichi Sato
Journal:  Sci Rep       Date:  2015-03-03       Impact factor: 4.379

4.  Value of thyroid transcription factor (TTF)-1 for diagnosis and prognosis of patients with locally advanced or metastatic small cell lung cancer.

Authors:  Daniel Misch; Torsten Blum; Christian Boch; Timo Weiss; Catharina Crolow; Sergej Griff; Thomas Mairinger; Torsten T Bauer; Jens Kollmeier
Journal:  Diagn Pathol       Date:  2015-04-02       Impact factor: 2.644

5.  TTF-1/p63-Positive Poorly Differentiated NSCLC: A Histogenetic Hypothesis from the Basal Reserve Cell of the Terminal Respiratory Unit.

Authors:  Daniela Cabibi; Sandro Bellavia; Antonino Giulio Giannone; Nadia Barraco; Calogero Cipolla; Anna Martorana; Vito Rodolico; Massimo Cajozzo; Ada Maria Florena
Journal:  Diagnostics (Basel)       Date:  2020-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.